Databridgemarketresearch.com Present “
Global RNA Therapeutics Market – Industry Trends and Forecast to 2028” new report to its research database. Due to the potential of SWOT analysis and Porter’s Five Forces analysis in generating market research report, they are preferred by the businesses and hence also used while making this report. To structure such a world-class report, the combination of best industry insight, practical solutions, talent solutions and latest technology have been used. As today’s businesses demand the market research analysis to a great extent before taking any verdict about the products, choosing such market research report is essential for the businesses. DBMR team is committed to present the market research report that is promising and the way in which it is foreseen.
Operator
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals conference call. [Operator Instructions] I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead, sir.
Vincent Anzalone
Vice President, Head of Investor Relations
Thanks, Aldan. Good afternoon, everyone. Thank you for joining us today to discuss Arrowhead s results for its fiscal 2021 first quarter ended December 31, 2020. With us today from management are President and CEO, Dr. Christopher Anzalone; who will provide an overview of the quarter; Dr. James Hamilton, our Senior Vice President of Discovery and Translational Medicine, who has graciously agreed to sub in for Dr. Javier San Martin while he is out ill today; and Ken Myszkowski, our Chief Financial Officer, who will give a review of the financials. In addition, James Hassard, our Chief Commercial Officer, will be available during the Q&A portion of today s call.
Our NanoNews Digest Sponsors
Home > Press > Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia.
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Pasadena. CA | Posted on January 25th, 2021
Javier San Martin, M.D., chief medical officer at Arrowhead, said: Cardiovascular disease remains the major cause of death, even after advances in therapies that reduce LDL cholesterol. This highlights the need for new therapies that can help patients at risk for cardiovascular disease to optimize their lipid profil